Apathy Treatment IRL757 Found Safe in Multiple Doses

A new medication, IRL757, is showing promise as a potential treatment for apathy—a common and often misunderstood symptom of Parkinson’s disease and other neurological conditions. 🧪 Safe and Well-Tolerated in Early Trials In a recent Phase 1 trial, multiple doses of IRL757 were tested in healthy volunteers and were found to be safe, well tolerated, and well absorbed, with no serious side effects reported. This builds on earlier findings from a single-dose study that also showed a strong safety profile. 👥 Next Step: Testing in People with Parkinson’s Thanks to these encouraging results, a Phase 1b trial is set to begin in late 2025. This next phase will explore how safe the medication is for people living with Parkinson’s—and whether it can help reduce apathy and improve motivation. Why This Matters Apathy affects many people with Parkinson’s and is more than just low energy—it involves a deep sense of disinterest or lack of motivation, which can impact quality of life, daily functioning, and emotional well-being. Right now, there are no approved treatments for apathy. 💊 How IRL757 Works IRL757 is taken by mouth and aims to restore disrupted brain signaling between regions that regulate emotions, thoughts, and behaviors. In early lab studies, it showed the potential to boost motivation and counteract apathy. 🎗️ Backed by Trusted Support This research is being funded in part by The Michael J. Fox Foundation, showing strong external confidence in the treatment’s potential. 📅 Looking Ahead As the research progresses, many are hopeful that IRL757 may one day offer a meaningful option to help people with Parkinson’s feel more engaged and motivated in their daily lives.